CSL investors will get a long-awaited look under the hood at the blood product giant’s strategy for its newly acquired business Vifor on Monday. It will be the first detailed overview of its vision for the business since announcing the multi-billion dollar acquisition in December last year.of the Swiss renal therapy and iron deficiency products business.Abrdn head of Australian equities Michelle Lopez says there has been “very little information” shared to date for such a large acquisition.
Abrdn’s Michelle Lopez says there’s some key questions investors want answered about the Vifor business.Ms Lopez said one of the critical issues for investors is CSL’s plan for when Vifor’s patents expire on its leading iron deficiency product Ferinject, due to take place in Europe in 2023 and in the US in 2028.
“American Regent received about two-thirds of revenue generated from distributing the drug in America. That’s a very high amount to be paying away,” she said.
big company is always itching to grow bigger Rio had paid top$ to buy up aluminium at the top then they nearly went insolvent during GFC Just GREED